
SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,
Summary
Shares of SELLAS Life Sciences surged to a new 52-week high alongside massive trading volume following positive results from a late-stage clinical trial. The company reported successful data from a pivotal study evaluating its cancer vaccine designed to treat acute myeloid leukemia.
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to Benzinga Pro data. The company released positive topline results from its pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia…
Source: Read the full story at Top Stories Feed